Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients

Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients

Abstract Background Pyrotinib was well tolerated but its efficacy was unsatisfactory in patients with HER2‐positive gastric cancer (GC) (NCT02378389). This study was to optimize the efficacy of pyrotinib. Methods Human GC cell lines and AVATAR mice were used to explore the refractory mechanisms of p...

Full description

Bibliographic Details
Main Authors: Zuhua Chen, Yingying Xu, Jifang Gong, Furong Kou, Mengqi Zhang, Tiantian Tian, Xiaotian Zhang, Cheng Zhang, Jian Li, Zhongwu Li, Yumei Lai, Jianjun Zou, Xiaoyu Zhu, Jing Gao, Lin Shen
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Clinical and Translational Medicine
Subjects:
CDK inhibitor
pyrotinib
refractory mechanisms
Online Access:https://doi.org/10.1002/ctm2.148

Internet

https://doi.org/10.1002/ctm2.148

Similar Items